Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Trauma and Emergency Surgery
Published in: European Journal of Trauma and Emergency Surgery 4/2018

01-08-2018 | Original Article

Mesenchymal stem cells in peripheral blood of severely injured patients

Authors: R. Wiegner, N.-E. Rudhart, E. Barth, F. Gebhard, L. Lampl, M. S. Huber-Lang, R. E. Brenner

Published in: European Journal of Trauma and Emergency Surgery | Issue 4/2018

Login to get access

Abstract

Purpose

Mesenchymal stem cells (MSCs) are primarily stromal cells present in bone marrow and other tissues that are crucial for tissue regeneration and can be mobilized into peripheral blood after different types of organ damage. However, little is known about MSC appearance in blood in the setting of polytrauma.

Methods

We conducted a monocentered and longitudinal observational clinical study in 11 polytraumatized patients with an injury severity score (ISS) ≥ 24 to determine the numbers of MSCs in peripheral blood. Blood was collected from healthy volunteers and patients after polytrauma in the emergency room and 4, 12, 24, 48 h, 5 and 10 day later, and cells carrying MSC-surface markers (negative for CD45, positive for CD29, CD73, CD90, CD105, and CD166 in different combinations also employing the more stringent markers STRO1 and MSCA1) were detected and characterized using flow cytometry. Relative numbers of MSC-like cells were correlated with clinical parameters to evaluate if specific injury patterns had an influence on their presence in the blood cell pool.

Results

We were able to detect MSC marker-positive cells in both cohorts; however, the percentage of those cells present in the blood of patients during the first 10 day after injury was mostly similar to healthy volunteers, and significantly lowers starting at 4 h post trauma for one marker combination when compared to controls. Furthermore, the presence of a pelvis fracture was partly correlated with reduced relative numbers of MSC-like cells detectable in blood.

Conclusions

Polytrauma in humans was associated with partly reduced relative numbers of MSC-like cells detected in peripheral blood in the time course after injury. Further studies need to define if this reduction was due to lower mobilization from the bone marrow or to active migration to the sites of injury.
Literature
1.
Haagsma JA, Graetz N, Bolliger I, Naghavi M, Higashi H, Mullany EC, et al. The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the global burden of disease study 2013. Inj Prev. 2016;22:3–18.CrossRefPubMed
2.
Mokdad AH, Forouzanfar MH, Daoud F, Mokdad AA, El BC, Moradi-Lakeh M, et al. Global burden of diseases, injuries, and risk factors for young people’s health during 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2016;387:2383–401.CrossRefPubMed
3.
4.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.CrossRefPubMed
5.
Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71–4.CrossRefPubMed
6.
Fickert S, Fiedler J, Brenner RE. Identification of subpopulations with characteristics of mesenchymal progenitor cells from human osteoarthritic cartilage using triple staining for cell surface markers. Arthritis Res Ther. 2004;6:R422–32.CrossRefPubMedPubMedCentral
7.
Fickert S, Fiedler J, Brenner RE. Identification, quantification and isolation of mesenchymal progenitor cells from osteoarthritic synovium by fluorescence automated cell sorting. Osteoarthr Cartil. 2003;11:790–800.CrossRefPubMed
8.
Klimczak A, Kozlowska U. Mesenchymal stromal cells and tissue-specific progenitor cells: their role in tissue homeostasis. Stem Cells Int. 2016;2016:4285215.CrossRefPubMed
9.
Murray IR, West CC, Hardy WR, James AW, Park TS, Nguyen A, et al. Natural history of mesenchymal stem cells, from vessel walls to culture vessels. Cell Mol Life Sci. 2014;71:1353–74.CrossRefPubMed
10.
Fu X, Fang L, Li X, Cheng B, Sheng Z. Enhanced wound-healing quality with bone marrow mesenchymal stem cells autografting after skin injury. Wound Repair Regen. 2006;14:325–35.CrossRefPubMed
11.
Saito T, Kuang JQ, Bittira B, Al-Khaldi A, Chiu RC. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg. 2002;74:19–24.CrossRefPubMed
12.
Dominici M, Le BK, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Int Soc Cell Ther Pos Statement Cytother. 2006;8:315–7.
13.
14.
Hengartner NE, Fiedler J, Schrezenmeier H, Huber-Lang M, Brenner RE. Crucial role of IL1beta and C3a in the in vitro-response of multipotent mesenchymal stromal cells to inflammatory mediators of polytrauma. PLoS One. 2015;10:e0116772.CrossRefPubMedPubMedCentral
15.
Granero-Molto F, Weis JA, Miga MI, Landis B, Myers TJ, O’Rear L, et al. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells. 2009;27:1887–98.CrossRefPubMedPubMedCentral
16.
Li L, Jiang J. Regulatory factors of mesenchymal stem cell migration into injured tissues and their signal transduction mechanisms. Front Med. 2011;5:33–9.CrossRefPubMed
17.
Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA. 2003;100:8407–11.CrossRefPubMed
18.
Gore AV, Bible LE, Song K, Livingston DH, Mohr AM, Sifri ZC. Mesenchymal stem cells increase T-regulatory cells and improve healing following trauma and hemorrhagic shock. J Trauma Acute Care Surg. 2015;79:48–52.CrossRefPubMedPubMedCentral
19.
Gore AV, Bible LE, Livingston DH, Mohr AM, Sifri ZC. Can mesenchymal stem cells reverse chronic stress-induced impairment of lung healing following traumatic injury? J Trauma Acute Care Surg. 2015;78:767–72.CrossRefPubMedPubMedCentral
20.
Hoogduijn MJ, Verstegen MM, Engela AU, Korevaar SS, Roemeling-van RM, Merino A, et al. No evidence for circulating mesenchymal stem cells in patients with organ injury. Stem Cells Dev. 2014;23:2328–35.CrossRefPubMed
21.
Seebach C, Henrich D, Tewksbury R, Wilhelm K, Marzi I. Number and proliferative capacity of human mesenchymal stem cells are modulated positively in multiple trauma patients and negatively in atrophic nonunions. Calcif Tissue Int. 2007;80:294–300.CrossRefPubMed
22.
Alm JJ, Koivu HM, Heino TJ, Hentunen TA, Laitinen S, Aro HT. Circulating plastic adherent mesenchymal stem cells in aged hip fracture patients. J Orthop Res. 2010;28:1634–42.CrossRefPubMed
23.
Eghbali-Fatourechi GZ, Lamsam J, Fraser D, Nagel D, Riggs BL, Khosla S. Circulating osteoblast-lineage cells in humans. N Engl J Med. 2005;352:1959–66.CrossRefPubMed
24.
He Q, Wan C, Li G. Concise review: multipotent mesenchymal stromal cells in blood. Stem Cells. 2007;25:69–77.CrossRefPubMed
25.
26.
Mansilla E, Marin GH, Drago H, Sturla F, Salas E, Gardiner C, et al. Bloodstream cells phenotypically identical to human mesenchymal bone marrow stem cells circulate in large amounts under the influence of acute large skin damage: new evidence for their use in regenerative medicine. Transpl Proc. 2006;38:967–9.CrossRef
27.
Ramirez M, Lucia A, Gomez-Gallego F, Esteve-Lanao J, Perez-Martinez A, Foster C, et al. Mobilisation of mesenchymal cells into blood in response to skeletal muscle injury. Br J Sports Med. 2006;40:719–22.CrossRefPubMedPubMedCentral
28.
Rochefort GY, Delorme B, Lopez A, Herault O, Bonnet P, Charbord P, et al. Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells. 2006;24:2202–8.CrossRefPubMed
29.
Xu L, Li G. Circulating mesenchymal stem cells and their clinical implications. J Orthop Transl. 2014;2:1–7.
30.
Zvaifler NJ, Marinova-Mutafchieva L, Adams G, Edwards CJ, Moss J, Burger JA, et al. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res. 2000;2:477–88.CrossRefPubMedPubMedCentral
31.
Pignolo RJ, Kassem M. Circulating osteogenic cells: implications for injury, repair, and regeneration. J Bone Miner Res. 2011;26:1685–93.CrossRefPubMed
32.
Wang Y, Johnsen HE, Mortensen S, Bindslev L, Ripa RS, Haack-Sorensen M, et al. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart. 2006;92:768–74.CrossRefPubMed
33.
Gebhard F, Huber-Lang M. Polytrauma–pathophysiology and management principles. Langenbecks Arch Surg. 2008;393:825–31.CrossRefPubMed
34.
Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells. Ann N Y Acad Sci. 2009;1176:101–17.CrossRefPubMed
35.
Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991;78:55–62.PubMed
36.
Kim YH, Yoon DS, Kim HO, Lee JW. Characterization of different subpopulations from bone marrow-derived mesenchymal stromal cells by alkaline phosphatase expression. Stem Cells Dev. 2012;21:2958–68.CrossRefPubMedPubMedCentral
37.
Lv FJ, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014;32:1408–19.CrossRefPubMed
38.
Marlicz W, Zuba-Surma E, Kucia M, Blogowski W, Starzynska T, Ratajczak MZ. Various types of stem cells, including a population of very small embryonic-like stem cells, are mobilized into peripheral blood in patients with Crohn’s disease. Inflamm Bowel Dis. 2012;18:1711–22.CrossRefPubMed
39.
Starzynska T, Dabkowski K, Blogowski W, Zuba-Surma E, Budkowska M, Salata D, et al. An intensified systemic trafficking of bone marrow-derived stem/progenitor cells in patients with pancreatic cancer. J Cell Mol Med. 2013;17:792–9.CrossRefPubMedPubMedCentral
40.
Blogowski W, Zuba-Surma E, Salata D, Budkowska M, Dolegowska B, Starzynska T. Peripheral trafficking of bone-marrow-derived stem cells in patients with different types of gastric neoplasms. Oncoimmunology. 2016;5:e1099798.CrossRefPubMed
41.
Ferensztajn-Rochowiak E, Kucharska-Mazur J, Samochowiec J, Ratajczak MZ, Michalak M, Rybakowski JK. The effect of long-term lithium treatment of bipolar disorder on stem cells circulating in peripheral blood. World J Biol Psychiatry 2017;18(1):54–62.CrossRefPubMed
42.
Marketou ME, Parthenakis FI, Kalyva A, Pontikoglou C, Maragkoudakis S, Kontaraki JE, et al. Increased mobilization of mesenchymal stem cells in patients with essential hypertension: the effect of left ventricular hypertrophy. J Clin Hypertens (Greenwich). 2014;16:883–8.CrossRef
43.
Marketou ME, Parthenakis FI, Kalyva A, Pontikoglou C, Maragkoudakis S, Kontaraki JE, et al. Circulating mesenchymal stem cells in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2015;24:149–53.CrossRefPubMed
44.
Sielatycka K, Poniewierska-Baran A, Nurek K, Torbe A, Ratajczak MZ. Novel view on umbilical cord blood and maternal peripheral blood-an evidence for an increase in the number of circulating stem cells on both sides of the fetal-maternal circulation barrier. Stem Cell Rev. 2017. doi:10.​1007/​s12015-017-9763-z.PubMedPubMedCentralCrossRef
45.
Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739–49.CrossRefPubMed
46.
Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012;3:297.CrossRefPubMedPubMedCentral
47.
Naaldijk Y, Johnson AA, Ishak S, Meisel HJ, Hohaus C, Stolzing A. Migrational changes of mesenchymal stem cells in response to cytokines, growth factors, hypoxia, and aging. Exp Cell Res. 2015;338:97–104.CrossRefPubMed
48.
Hocking AM. The role of chemokines in mesenchymal stem cell homing to wounds. Adv Wound Care (New Rochelle). 2015;4:623–30.CrossRef
49.
Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Bruckner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg. 2000;135:291–5.CrossRefPubMed
50.
von BR, Oikonomou, Sulaj D, Mohammed A, Hotz-Wagenblatt S, Grone A. HJ et al.: CD166/ALCAM mediates proinflammatory effects of S100B in delayed type hypersensitivity. J Immunol. 2013;191:369–77.CrossRefPubMedPubMedCentral
51.
Esteve D, Galitzky J, Bouloumie A, Fonta C, Buchet R, Magne D. Multiple functions of MSCA-1/TNAP in adult mesenchymal progenitor/stromal cells. Stem Cells Int. 2016;2016:1815982.CrossRefPubMed
52.
53.
Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7:e2062.CrossRefPubMedPubMedCentral
Metadata
Title
Mesenchymal stem cells in peripheral blood of severely injured patients
Authors
R. Wiegner
N.-E. Rudhart
E. Barth
F. Gebhard
L. Lampl
M. S. Huber-Lang
R. E. Brenner
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Trauma and Emergency Surgery / Issue 4/2018
Print ISSN: 1863-9933
Electronic ISSN: 1863-9941
DOI
https://doi.org/10.1007/s00068-017-0849-8

Other articles of this Issue 4/2018

European Journal of Trauma and Emergency Surgery 4/2018 Go to the issue

Review Article

Could resuscitative endovascular balloon occlusion of the aorta improve survival among severely injured patients with post-intubation hypotension?

Original Article

Using emergency trauma team activations to measure trauma activity and injury severity: 10 years of experience using an Australian major trauma centre registry

Original Article

The use of aortic balloon occlusion in traumatic shock: first report from the ABO trauma registry

Original Article

Resuscitative endovascular balloon occlusion of the aorta: what is the optimum occlusion time in an ovine model of hemorrhagic shock?

Original Article

Evaluation of acute kidney injury (AKI) with RIFLE, AKIN, CK, and KDIGO in critically ill trauma patients

Original Article

Expanding the field of acute care surgery: a systematic review of the use of resuscitative endovascular balloon occlusion of the aorta (REBOA) in cases of morbidly adherent placenta